SG11201901790YA - Stabilized group 2 influenza hemagglutinin stem region trimers and uses thereof - Google Patents
Stabilized group 2 influenza hemagglutinin stem region trimers and uses thereofInfo
- Publication number
- SG11201901790YA SG11201901790YA SG11201901790YA SG11201901790YA SG11201901790YA SG 11201901790Y A SG11201901790Y A SG 11201901790YA SG 11201901790Y A SG11201901790Y A SG 11201901790YA SG 11201901790Y A SG11201901790Y A SG 11201901790YA SG 11201901790Y A SG11201901790Y A SG 11201901790YA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- nanoparticles
- trimers
- group
- influenza
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
- G01N33/54346—Nanoparticles
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
- C07K2319/42—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a HA(hemagglutinin)-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/11—Orthomyxoviridae, e.g. influenza virus
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2469/00—Immunoassays for the detection of microorganisms
- G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Nanotechnology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662383267P | 2016-09-02 | 2016-09-02 | |
| PCT/US2017/049894 WO2018045308A1 (en) | 2016-09-02 | 2017-09-01 | Stabilized group 2 influenza hemagglutinin stem region trimers and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201901790YA true SG11201901790YA (en) | 2019-03-28 |
Family
ID=59887401
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201901790YA SG11201901790YA (en) | 2016-09-02 | 2017-09-01 | Stabilized group 2 influenza hemagglutinin stem region trimers and uses thereof |
| SG10201912944QA SG10201912944QA (en) | 2016-09-02 | 2017-09-01 | Stabilized group 2 influenza hemagglutinin stem region trimers and uses thereof |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201912944QA SG10201912944QA (en) | 2016-09-02 | 2017-09-01 | Stabilized group 2 influenza hemagglutinin stem region trimers and uses thereof |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US11338033B2 (enExample) |
| EP (1) | EP3506938A1 (enExample) |
| JP (3) | JP7183149B2 (enExample) |
| KR (2) | KR20190056382A (enExample) |
| CN (2) | CN110167585B (enExample) |
| AU (2) | AU2017321883B2 (enExample) |
| BR (1) | BR112019004189A2 (enExample) |
| CA (1) | CA3035443A1 (enExample) |
| IL (3) | IL303650B2 (enExample) |
| SG (2) | SG11201901790YA (enExample) |
| WO (1) | WO2018045308A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3906939A1 (en) | 2013-10-11 | 2021-11-10 | The United States of America, represented by the Secretary, Department of Health and Human Services | Epstein-barr virus vaccines |
| KR20190056382A (ko) * | 2016-09-02 | 2019-05-24 | 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 | 안정화된 그룹 2 인플루엔자 헤마글루티닌 줄기 영역 삼량체 및 그의 용도 |
| GB2578163A (en) * | 2018-10-19 | 2020-04-22 | Univ Pretoria | Plant produced avian influenza antigens and their uses in diagnostic assays and devices |
| US12433943B2 (en) | 2019-02-08 | 2025-10-07 | University Of Washington | Nanoparticle-based influenza virus vaccines and uses thereof |
| WO2021174132A2 (en) * | 2020-02-26 | 2021-09-02 | The Wistar Institute Of Anatomy & Biology | Compositions comprising self-assembling vaccines and methods of using the same |
| CN111560074B (zh) * | 2020-03-20 | 2021-07-09 | 中山大学 | 一种基于幽门螺旋杆菌铁蛋白的新型冠状病毒s蛋白单区域亚单位纳米疫苗 |
| WO2021231729A1 (en) | 2020-05-13 | 2021-11-18 | Sanofi | Adjuvanted stabilized stem hemagglutinin nanoparticles and methods of using the same to induce broadly neutralizing antibodies against influenza |
| MX2023011400A (es) | 2021-03-26 | 2023-10-09 | Glaxosmithkline Biologicals Sa | Composiciones inmunogenicas. |
| US20240165224A1 (en) | 2021-03-26 | 2024-05-23 | Glaxosmithkline Biologicals Sa | Immunogenic compositions |
| EP4362974A1 (en) | 2021-06-28 | 2024-05-08 | GlaxoSmithKline Biologicals S.A. | Novel influenza antigens |
| AU2022345984A1 (en) | 2021-09-16 | 2024-04-04 | Emergent Product Development Gaithersburg Inc. | Vaccine compositions |
| WO2023061993A1 (en) | 2021-10-13 | 2023-04-20 | Glaxosmithkline Biologicals Sa | Polypeptides |
| GB202219228D0 (en) | 2022-12-20 | 2023-02-01 | Glaxosmithkline Biologicals Sa | Novel influenza antigens |
| CN115850396B (zh) * | 2022-12-22 | 2024-02-06 | 北京吉诺卫生物科技有限公司 | 一种rsv纳米颗粒疫苗及其制备方法与应用 |
| WO2024131862A1 (zh) * | 2022-12-22 | 2024-06-27 | 北京吉诺卫生物科技有限公司 | 一种rsv疫苗及其制备方法与应用 |
| WO2024163912A2 (en) * | 2023-02-03 | 2024-08-08 | The Children's Medical Center Corporation | Vaccine and therapeutic protein delivery compositions comprising fusion proteins |
| WO2024167855A1 (en) | 2023-02-06 | 2024-08-15 | Emergent Product Development Gaithersburg Inc. | Influenza hemagglutinin constructs and compositions |
| WO2024197134A1 (en) * | 2023-03-21 | 2024-09-26 | President And Fellows Of Harvard College | Coronavirus spike protein-based vaccines |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6337070B1 (en) | 1993-04-29 | 2002-01-08 | Takara Shuzo Co., Ltd. | Polypeptides for use in generating anti-human influenza virus antibodies |
| AUPQ912000A0 (en) | 2000-07-31 | 2000-08-24 | Crown In The Right Of The Queensland Department Of Health, The | Improved virus like particles |
| CA2462455C (en) | 2001-10-01 | 2012-07-17 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Development of a preventive vaccine for filovirus infection in primates |
| US20050108791A1 (en) | 2001-12-04 | 2005-05-19 | Edgerton Michael D. | Transgenic plants with improved phenotypes |
| US7097841B2 (en) | 2002-05-10 | 2006-08-29 | New Century Pharmaceuticals, Inc. | Ferritin fusion proteins for use in vaccines and other applications |
| JP4726483B2 (ja) | 2002-07-17 | 2011-07-20 | サイトス バイオテクノロジー アーゲー | 分子抗原アレイ |
| US20060130158A1 (en) | 2002-08-30 | 2006-06-15 | Turner Andrew J | Modified transferrin fusion proteins comprising duplicate transferrin amino or carboxy terminal domains |
| WO2005018539A2 (en) | 2003-06-16 | 2005-03-03 | Medimmune Vaccines, Inc. | Influenza hemagglutinin and neuraminidase variants |
| GB0319797D0 (en) | 2003-08-26 | 2003-09-24 | Leuven K U Res & Dev | Particle size reduction of poorly soluble drugs |
| US7897408B2 (en) | 2005-09-12 | 2011-03-01 | Japan Science And Technology Agency | Method for producing CdS-apoferritin and ZnS-apoferritin complexes |
| ES2555544T3 (es) | 2006-03-07 | 2016-01-04 | Vaxinnate Corporation | Composiciones que incluyen hemaglutinina, métodos de preparación y métodos de uso de las mismas |
| WO2008087563A2 (en) | 2006-12-29 | 2008-07-24 | Institut Pasteur Of Shanghai | Lentivirus pseudotyped with influenza hemagglutinin and methods of use |
| WO2008145129A2 (en) | 2007-05-31 | 2008-12-04 | Statens Serum Institut | Influenza vaccines |
| US8778847B2 (en) | 2007-06-13 | 2014-07-15 | The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Immunogenic peptides of influenza virus |
| CA2696764A1 (en) | 2007-08-20 | 2009-02-26 | Fraunhofer Usa, Inc. | Prophylactic and therapeutic influenza vaccines, antigens, compositions, and methods |
| WO2009109428A2 (en) | 2008-02-01 | 2009-09-11 | Alpha-O Peptides Ag | Self-assembling peptide nanoparticles useful as vaccines |
| JP5382489B2 (ja) | 2008-03-29 | 2014-01-08 | 国立大学法人 奈良先端科学技術大学院大学 | 円偏光発光性ナノ微粒子 |
| US20110177122A1 (en) | 2008-09-26 | 2011-07-21 | The United States Of America, As Represented By The Secretary, Dept. Of Health & Human Services | Dna prime/activated vaccine boost immunization to influenza virus |
| JP2012521786A (ja) * | 2009-03-30 | 2012-09-20 | モウント シナイ スクール オフ メディシネ | インフルエンザウイルスワクチン及びその使用 |
| SG178918A1 (en) | 2009-09-22 | 2012-04-27 | Medicago Inc | Method of preparing plant-derived vlps |
| US20120219584A1 (en) | 2009-10-05 | 2012-08-30 | The United States Of America As Represented By The Secretary, Department Of Health | Protection against pandemic and seasonal strains of influenza |
| CA2789945A1 (en) | 2010-02-18 | 2011-08-25 | Technovax, Inc. | Universal virus-like particle (vlp) influenza vaccines |
| EP2652496B1 (en) * | 2010-12-13 | 2018-01-17 | The University of Utah Research Foundation | Vaccine antigens that direct immunity to conserved epitopes |
| WO2012162428A1 (en) | 2011-05-23 | 2012-11-29 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Prime-boost vaccination for viral infection |
| HK1200102A1 (en) | 2011-09-20 | 2015-07-31 | 西奈山医学院 | Influenza virus vaccines and uses thereof |
| WO2013044203A2 (en) | 2011-09-23 | 2013-03-28 | THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPTARTMENT OF HEALTH & HUMAN SERVICES | Novel influenza hemagglutinin protein-based vaccines |
| AU2012343981B2 (en) | 2011-11-28 | 2017-09-07 | Janssen Vaccines & Prevention B.V. | Influenza virus vaccines and uses thereof |
| WO2013177444A2 (en) | 2012-05-23 | 2013-11-28 | The Board Of Trustees Of The Leland Stanford Junior University | Influenza vaccine constructs |
| NZ627796A (en) | 2012-12-18 | 2017-07-28 | Icahn School Med Mount Sinai | Influenza virus vaccines and uses thereof |
| CA2913859C (en) * | 2013-05-30 | 2021-11-30 | Crucell Holland B.V. | Influenza virus vaccines and uses thereof |
| EP3906939A1 (en) | 2013-10-11 | 2021-11-10 | The United States of America, represented by the Secretary, Department of Health and Human Services | Epstein-barr virus vaccines |
| CN111500631B (zh) | 2013-10-28 | 2024-03-29 | 蓝天免疫疗法有限责任公司 | 用于病毒疗法的新型流感病毒载体 |
| PT3148578T (pt) * | 2014-05-27 | 2022-08-23 | Us Health | Trímeros estabilizados da região do caule da hemaglutinina do vírus da gripe e suas utilizações |
| SG11201610456UA (en) | 2014-07-10 | 2017-01-27 | Janssen Vaccines & Prevention Bv | Influenza virus vaccines and uses thereof |
| CN106795513B (zh) | 2014-08-08 | 2021-06-11 | Vlp治疗公司 | 包含修饰的包膜蛋白e3的病毒样颗粒 |
| KR102713707B1 (ko) | 2014-12-31 | 2024-10-04 | 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 | 신규 다가 나노입자 기반 백신 |
| WO2018005558A1 (en) | 2016-06-27 | 2018-01-04 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Self-assembling insect ferritin nanoparticles for display of co-assembled trimeric antigens |
| KR20190056382A (ko) * | 2016-09-02 | 2019-05-24 | 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 | 안정화된 그룹 2 인플루엔자 헤마글루티닌 줄기 영역 삼량체 및 그의 용도 |
| WO2021231729A1 (en) * | 2020-05-13 | 2021-11-18 | Sanofi | Adjuvanted stabilized stem hemagglutinin nanoparticles and methods of using the same to induce broadly neutralizing antibodies against influenza |
-
2017
- 2017-09-01 KR KR1020197009334A patent/KR20190056382A/ko not_active Ceased
- 2017-09-01 IL IL303650A patent/IL303650B2/en unknown
- 2017-09-01 KR KR1020247010062A patent/KR20240042570A/ko active Pending
- 2017-09-01 CA CA3035443A patent/CA3035443A1/en active Pending
- 2017-09-01 SG SG11201901790YA patent/SG11201901790YA/en unknown
- 2017-09-01 SG SG10201912944QA patent/SG10201912944QA/en unknown
- 2017-09-01 CN CN201780066267.2A patent/CN110167585B/zh active Active
- 2017-09-01 BR BR112019004189-3A patent/BR112019004189A2/pt unknown
- 2017-09-01 IL IL265121A patent/IL265121B2/en unknown
- 2017-09-01 AU AU2017321883A patent/AU2017321883B2/en active Active
- 2017-09-01 IL IL315821A patent/IL315821A/en unknown
- 2017-09-01 CN CN202410185751.9A patent/CN118146389A/zh active Pending
- 2017-09-01 US US16/329,592 patent/US11338033B2/en active Active
- 2017-09-01 EP EP17768316.6A patent/EP3506938A1/en active Pending
- 2017-09-01 WO PCT/US2017/049894 patent/WO2018045308A1/en not_active Ceased
- 2017-09-01 JP JP2019512267A patent/JP7183149B2/ja active Active
-
2022
- 2022-05-11 US US17/742,201 patent/US11793871B2/en active Active
- 2022-10-07 AU AU2022246465A patent/AU2022246465B2/en active Active
- 2022-11-22 JP JP2022186724A patent/JP7500692B2/ja active Active
-
2023
- 2023-10-20 US US18/491,193 patent/US12527857B2/en active Active
-
2024
- 2024-06-05 JP JP2024091170A patent/JP2024123036A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2022246465B2 (en) | 2024-05-30 |
| IL265121A (enExample) | 2019-04-30 |
| AU2017321883B2 (en) | 2022-07-07 |
| US20190192651A1 (en) | 2019-06-27 |
| AU2017321883A1 (en) | 2019-04-18 |
| IL303650B1 (en) | 2024-10-01 |
| JP2024123036A (ja) | 2024-09-10 |
| US20240050554A1 (en) | 2024-02-15 |
| JP2023018073A (ja) | 2023-02-07 |
| IL303650A (en) | 2023-08-01 |
| CN110167585A (zh) | 2019-08-23 |
| EP3506938A1 (en) | 2019-07-10 |
| JP2019537424A (ja) | 2019-12-26 |
| SG10201912944QA (en) | 2020-02-27 |
| KR20240042570A (ko) | 2024-04-02 |
| IL265121B2 (en) | 2023-11-01 |
| KR20190056382A (ko) | 2019-05-24 |
| IL265121B1 (en) | 2023-07-01 |
| US12527857B2 (en) | 2026-01-20 |
| IL303650B2 (en) | 2025-02-01 |
| AU2022246465A1 (en) | 2022-11-17 |
| BR112019004189A2 (pt) | 2019-06-25 |
| CN118146389A (zh) | 2024-06-07 |
| US20220339278A1 (en) | 2022-10-27 |
| CA3035443A1 (en) | 2018-03-08 |
| CN110167585B (zh) | 2024-03-08 |
| WO2018045308A1 (en) | 2018-03-08 |
| US11793871B2 (en) | 2023-10-24 |
| IL315821A (en) | 2024-11-01 |
| JP7500692B2 (ja) | 2024-06-17 |
| US11338033B2 (en) | 2022-05-24 |
| JP7183149B2 (ja) | 2022-12-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201807912SA (en) | Vaccine against rsv | |
| SG11201909153UA (en) | Peptides and combination thereof for use in the immunotherapy against cancers | |
| SG11201909265QA (en) | Plasmodium sporozoite npdp peptides as vaccine and target novel malaria vaccines and antibodies binding to | |
| SG11201900955VA (en) | T cell receptors and immune therapy using the same | |
| SG11201908540PA (en) | Stable antibody formulation | |
| SG11201906198PA (en) | Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers | |
| SG11201900482SA (en) | Compounds and compositions as inhibitors of endosomal toll-like receptors | |
| SG11201811363YA (en) | Anti-zika virus antibodies and methods of use | |
| SG11201901206SA (en) | Trimer stabilizing hiv envelope protein mutations | |
| SG11201906297QA (en) | Nucleic acids encoding crispr-associated proteins and uses thereof | |
| SG11201809336QA (en) | Anti-pd-l1 antibodies | |
| SG11201809700YA (en) | Gdf15 fusion proteins and uses thereof | |
| SG11201907867TA (en) | Use of anti-ctla-4 antibodies with enhanced adcc to enhance immune response to a vaccine | |
| SG11201809879WA (en) | Novel antibodies specifically binding to zika virus epitopes and uses thereof | |
| SG11201907754RA (en) | Anti-phf-tau antibodies and uses thereof | |
| SG11201905699XA (en) | Anti-icos agonist antibodies and uses thereof | |
| SG11201903867YA (en) | Antibodies directed against t cell immunoglobulin and mucin protein 3 (tim-3) | |
| SG11201907451XA (en) | Substituted imidazo-quinolines as nlrp3 modulators | |
| SG11201810801QA (en) | Brain delivery protein | |
| SG11201906392WA (en) | Nucleoside-modified rna for inducing an immune response against zika virus | |
| SG11201809229VA (en) | Pharmaceutical composition | |
| SG11201808750PA (en) | T cell receptors | |
| SG11201809374VA (en) | Cd40l-fc fusion polypeptides and methods of use thereof | |
| SG11201806121PA (en) | Ror2 antibody compositions and related methods | |
| SG11201804411TA (en) | Human immunodeficiency virus antigens, vectors, compositions, and methods of use thereof |